You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

31 Items
Cancer Type: Hematologic, Lymphoma - Hodgkin     
Intent: Curative
Funding:
ODB - General Benefit
    procarbazine
ODB - General Benefit
    prednisone
Jun 2019
Cancer Type: Gastrointestinal, Esophagus, Gastric / Stomach     
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Jun 2019
Cancer Type: Head and Neck     
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
May 2019
Cancer Type: Head and Neck     
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Aug 2019
Cancer Type: Gastrointestinal, Esophagus, Gastric / Stomach     
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Drugs Used:
trastuzumab (PDRP prior authorization),
Updated
Nov 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade, Lymphoma - T-cell     
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
ODB - General Benefit
    etoposide - oral capsules
May 2018
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (SC) - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (SC) - HIV-Related - Aggressive Histology - B-cell Lymphoma
New Drug Funding Program
    Rituximab - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab - HIV-Related, Aggressive Histology, B-cell Lymphoma
Jul 2018
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    prednisone
Jul 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jul 2019
Cancer Type: Hematologic, Lymphoma - T-cell     
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
May 2018
Cancer Type: Hematologic, Rare Diseases, Sarcoma     
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jun 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
May 2019